Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Moore et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69dbda929e6f14d6f16846e9 — DOI: https://doi.org/10.1056/nejmoa2309169

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study· 2023 · 353 citations
2. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study· 2021 · 396 citations
3. Folate receptor alpha as a tumor target in epithelial ovarian cancer· 2008 · 461 citations
4. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue.· 2009 · 129 citations
5. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial· 2014 · 1,617 citations